TIB Molbiol

2022年8月23日

罗氏及其子公司TIB Molbiol为研究人员开发了一种COVID-19检测方法，可以检测和区分BA.2.75的最新亚变体。该测试专门针对BA.2.75中已知的两个独特突变，这允许与其他显著的亚变体有明显的区别。罗氏诊断解决方案分子实验室负责人Cindy Perettie说:“罗氏很高兴为研究人员开发了一种检测方法，可以深入了解BA.2.75的流行病学，帮助了解其对公共卫生的影响。”“能够区分新出现的变异，了解它们的相似性和突变，可以为专家预测它们的传播和对治疗策略的反应提供基础。”自2022年5月在印度首次发现BA.2.75病例以来，已有十多个国家报告了BA.2.75病例。BA.2.75是与欧米克隆变种相关的子变种。世界卫生组织和美国疾病控制与预防中心正在对这种亚变异进行监测。它还没有达到关注的变体的水平，但是将它与BA.4和BA.5区分开来，可以更好地跟踪以了解它是如何传播的。现有研究仅使用VirSNiP SARS-CoV-2 Spike 147E 152R检测试剂盒，这是罗氏和TIB Molbiol开发的广泛的COVID-19检测试剂盒的一部分，例如用于检测最近的BA.4和BA.5亚变体，以及Omicron SARS-CoV-2变体中存在的其他突变。罗氏和TIB Molbiol的研究人员继续与全球合作伙伴合作，不断筛查新的变异和新出现的疾病。 About the VirSNiP SARS-CoV-2 Spike 147E 152R The test specifically targets two of the known unique mutations, K147E and W152R, in BA.2.75, which allows clear differentiation against other notable subvariants. This test is for research use only and is available globally. The VirSNiP SARS-CoV-2 Spike 147E 152R for use on Lightcycler and cobas z480 analyzer. Responding to the COVID-19 pandemic As a leading healthcare company, we are doing all we can to support countries in their fight against COVID-19 and minimising its impact. That is why we are working with governments, policy makers, healthcare professionals and others to help contain the COVID-19 pandemic and make sure patients continue to receive the tests, treatment and care they need. The pandemic has profoundly raised awareness of the role diagnostics play in COVID-19 diagnosis, treatment development and disease management. Roche has developed and launched more than 20 COVID-19 diagnostics solutions, including polymerase chain reaction (PCR) and rapid antigen and antibody tests. Our solutions serve the entire diagnostic continuum, from high-throughput laboratories to point-of-care and home self-testing, and cover all currently known variants. To help meet global demand, we have supplied more than 1.5 billion tests for COVID-19 since March 2020. According to the company, its utmost goal remains to be a trusted partner who acts with urgency to save and improve the lives of patients with COVID-19 and to reduce its burden on society. For more information please visit the company’s COVID-19 response page . Share: